Subsequent Events |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2025 | |||
| Subsequent Events [Abstract] | |||
| Subsequent Events |
ATM
Subsequent to December 31, 2025, 1,000,000 shares of common stock were sold under the Leerink ATM for gross proceeds through March 12, 2026 in the amount of $2.3 million, before deducting issuance expenses, including the placement agent’s fees, in the amount of $0.1 million.
February Private
Placement
On February 13, 2026, the Company
entered into a securities purchase agreement for a private placement (the “February 2026 Private Placement”) of 7,374,632 shares
of Series B Non-Voting Convertible Preferred Stock at a price of $3.39 per share for gross proceeds of $25.0 million, before deducting offering expenses. The private placement closed on February 18, 2026.
Subject to Opus Genetics stockholder approval of an increase to the
authorized shares of common stock, each share of Series B Non-Voting Convertible Preferred Stock will automatically convert into one
share of common stock for an aggregate of 7,374,632 shares of common stock.
|